EORTC QLQ‐LC13
dyspnea, Dyspnea, pain, peripheral neuropathy, hemoptysis, −4.7, Cancer
PERIPHERAL NEUROPATHY, LUNG CANCER, PERIPHERAL NEUROPATHY, CANCER
Baseline means for the QLQ‐LC13 are presented in Table Change from Baseline for EORTC QLQ‐LC13. CI, confidence interval, EORTC QLQ‐LC13, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 items; LS, least squares.Dyspnea maintained in the tislelizumab arm at week 12 (LS mean change: −0.8 [95% CI: −2.42 to 0.73]) and improved at week 18 (LS mean change: −1.2 [95% CI: −2.93 to 0.56]). In the docetaxel arm dyspnea increased at both week 12 (LS mean change: 1.6 [95% CI: −0.87 to 4.16]) and week 18 (LS mean change: 2.0 [95% CI: −1.01 to 5.05]). The difference in change from baseline between the two arms was not significant at either week 12 (difference in LS mean change: −2.5 [95% CI: −5.24 to 0.26, Coughing improved in the tislelizumab arm at week 12 (−6.3 [95% CI: −8.56 to −4.11]) and week 18 (−7.8 [95% CI: −10.23 to −5.30]). The docetaxel arm improved at week 12 (−1.7 [95% CI: −5.23 to 1.91]) and maintained at week 18 (0.5 [95% CI: −3.87 to 4.87]). The difference in change from baseline between the two arms was statistically significant at week 12 (−4.7 [95% CI: −8.57 to −0.78, Peripheral neuropathy maintained in the tislelizumab arm at week 12 (LS mean change: −0.3 [95% CI: −1.90 to 1.38]) and improved at week 18 (LS mean change: ‐1.3 [95% CI: −3.12 to 0.46]). In the docetaxel arm peripheral neuropathy worsened at week 12 (LS mean change: 4.5 [95% CI: 1.84–7.13]) and at week 18 (LS mean change: 6.3 [95% CI: 3.09–9.46]). The difference in change from baseline between the two arms was significant at both week 12 (difference in LS mean change: −4.7 [95% CI: −7.64 to −1.85, For pain in chest, the tislelizumab arm at improved at week 12 (LS mean change: −2.0 [95% CI: −3.79 to −0.24]) and maintained in the docetaxel arm (LS mean change: −0.4 [95% CI: −3.25 to 2.51]). At week 18, the tislelizumab arm maintained (LS mean change: −0.9 [95% CI: −2.86 to 1.06]) and worsened in in the docetaxel arm (LS mean change: 1.3 [95% CI: −2.15 to 4.84]).The difference in change from baseline between the two arms was not significant at week 12 (difference in LS mean change: −1.6 [95% CI: −4.80 to 1.51, For pain in the arm or shoulder, the tislelizumab arm maintained at week 12 (LS mean change: −0.9 [95% CI: −2.74 to 0.92]) and improved at week 18 (LS mean change: −2.1 [95% CI: −4.11 to −0.18]). The docetaxel arm slightly improved at week 12 (LS mean change: −1.4 [95% CI: −4.32 to 1.55]) and maintained at week 18 (LS mean change: −0.4 [95% CI: −3.86 to 3.06]).The difference in change from baseline between the two arms was not significant at week 12 (difference in LS mean change: 0.5 [95% CI: −2.73 to 3.69, For hemoptysis the tislelizumab arm improved at both week 12 (LS mean change: −1.3 [95% CI: −2.61 to −0.01]) and week 18 (LS mean change: −1.3 [95% CI: −2.69 to 0.05]). The docetaxel arm maintained at week 12 (LS mean change: −0.2 [95% CI: −2.39 to 2.03]) and improved at week 18 (LS mean change: −2.2 [95% CI: −4.73 to 0.37]).The difference in change from baseline between the two arms was not significant at week 12 (difference in LS mean change: −1.1 [95% CI: −3.58 to 1.32, 